Thrombin is a distal mediator of lipopolysaccharide-induced liver injury in the rat.
Previous results demonstrated that rats given Escherichia coli lipopolysaccharide (LPS; 4 mg/kg, i.v.) experience hepatocellular necrosis that begins within 4 hr and that prior treatment with anticoagulants (e.g., heparin) which target thrombin prevents the liver injury. In this study, hepatocellular injury, as marked by increased plasma alanine aminotransferase (ALT) activity and histologic changes, was prevented when heparin or hirudin was administered to rats shortly before the onset of injury. These results suggest that thrombin is a critical mediator that acts distally in the series of inflammatory events that culminates in hepatocellular damage. To explore further this hypothesis, livers isolated from rats 2 hr after LPS administration were perfused with various media. Perfusion of livers with medium comprising diluted blood from heparin-treated donors resulted in no release of ALT activity. By contrast, perfusion with similar medium anticoagulated with ancrod, which prevents clotting by depleting fibrinogen but does not inhibit thrombin, resulted in hepatocellular injury evidenced as a time-dependent appearance of ALT activity in the medium. Moreover, when livers from rats treated 2 hr previously with LPS were perfused with buffer to which thrombin had been added, injury resulted. No injury resulted when thrombin was omitted from the buffer or when livers from saline-treated rats were used. These results indicate that thrombin is a critical and distal mediator of LPS-induced liver damage and contributes to hepatocellular injury through a mechanism that is independent of clot formation. Furthermore, inflammatory events triggered by LPS exposure are a prerequisite for thrombin-induced injury.
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, USA.
F
F
Moulin
J M
JM
Pearson
A E
AE
Schultze
M A
MA
Scott
K A
KA
Schwartz
J M
JM
Davis
P E
PE
Ganey
R A
RA
Roth
D000410:Alanine Transaminase / Q000097:blood / Q000187:drug effects; D000721:Ancrod / Q000494:pharmacology; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology; D000991:Antithrombins / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D005260:Female; D006493:Heparin / Q000494:pharmacology; D006629:Hirudins / Q000494:pharmacology; D066298:In Vitro Techniques; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008099:Liver / Q000187:drug effects / Q000473:pathology*; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D010477:Perfusion; D051381:Rats; D017207:Rats, Sprague-Dawley; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000502:physiology*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000925:Anticoagulants; D000991:Antithrombins; D006629:Hirudins; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D006493:Heparin; D000410:Alanine Transaminase; D000721:Ancrod; D013917:Thrombin